Roche wins new Evrysdi approval for the youngest SMA patients
Roche just turned the spinal muscular atrophy race up another notch.
The Big Pharma company won another FDA approval for its oral SMA drug Evrysdi, though Tuesday’s green light comes for babies younger than two months old. It’s the first such approval for any SMA drug available to administer at home in this infant population.
“The approval of Evrysdi for pre-symptomatic babies is particularly important, as early treatment of SMA, before symptoms start to arise, can help babies to achieve motor milestones,” Phase II principal investigator Richard Finkel said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.